General discussion, page-20219

too add, zepbound sales have hit $1b and it wasn’t available in the 2nd quarter last year. Yes it’s an injection but so is the treatment for diabetes. Given zepbound has high demand and enormous sales potential already, when it gets approval by the FDA to treat OSA, it could be lights out for ASX shareholders imo.

I can’t see how IHL will get FDA fast track approval for OSA if there’s a drug around that people can access - it will no longer be an unmet need soon. then, factor in that apnimed is making good progress with its oral treatment for osa. Its conducting phase 3 and top line results are due mid next year

no surprises why US investors aren’t interested